Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Progress in vaccination against AIDS]

A Burny1

  • 1UER Biologie moléculaire et Physiologie animale de la faculté des Sciences agronomiques de Gembloux.

Bulletin Et Memoires De L'Academie Royale De Medecine De Belgique
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Cellular dynamics of pathogenesis induced by bovine leukemia virus].

Virologie (Montrouge, France)·2022
Same author

[From fundamental research to translational research in oncology].

Revue medicale de Liege·2021
Same author

Monitoring molecular response in adult T-cell leukemia by high-throughput sequencing analysis of HTLV-1 clonality.

Leukemia·2017
Same author

Evolution of microRNA expression during human bronchial squamous carcinogenesis.

The European respiratory journal·2008
Same author

The role of NPM, p14arf and MDM2 in precursors of bronchial squamous cell carcinoma.

The European respiratory journal·2008
Same author

HTLV-I infection of WE17/10 CD4+ cell line leads to progressive alteration of Ca2+ influx that eventually results in loss of CD7 expression and activation of an antiapoptotic pathway involving AKT and BAD which paves the way for malignant transformation.

Leukemia·2007

Two AIDS virus vaccination trials showed promising results. Prophylactic vaccination protected macaques from simian immunodeficiency virus (SIV) disease, while therapeutic vaccination improved human immunodeficiency virus (HIV) patients' clinical status.

Area of Science:

  • Immunology
  • Virology
  • Vaccine Development

Background:

  • Acquired immunodeficiency syndrome (AIDS) remains a global health challenge.
  • Developing effective vaccines against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) is critical.
  • Understanding immune responses to viral infections is key to therapeutic interventions.

Purpose of the Study:

  • To evaluate the efficacy of a prophylactic vaccine against SIV in pig-tailed macaques.
  • To assess the therapeutic potential of an alpha interferon toxoid vaccine in HIV-1 infected patients.

Main Methods:

  • Prophylactic vaccination trial: Macaques received a Semliki forest virus (SFV) recombinant expressing SIV envelope protein to prevent SIV PBj14 infection.
  • Therapeutic vaccination trial: HIV-1 infected patients were vaccinated with an inactivated and immunogenic preparation of alpha interferons (toxoid).

Related Experiment Videos

  • Immune response and clinical outcomes were monitored in both trials.

    • Main Results:

    • Prophylactic vaccination did not prevent SIV infection but significantly protected macaques from disease progression and mortality.
    • Therapeutic vaccination in HIV-1 patients induced neutralizing anti-alpha interferon antibodies.
    • Lowered circulating alpha interferon levels and significant clinical improvement were observed in vaccinated HIV-1 patients.

    Conclusions:

    • Vaccination strategies can protect against AIDS-related diseases, even if infection is not prevented.
    • Alpha interferon toxoid vaccination shows therapeutic potential for HIV-1 infection by modulating the immune response.
    • Further research into novel vaccine approaches is warranted for effective AIDS virus control.